Drug class
Incretins clinical trials
A class of medicines: the studies that test any of its 8 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the incretins studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
1,179 studies that test it; most in 2008 (98); 1 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 3 |
| 2000 | 1 |
| 2001 | 6 |
| 2002 | 9 |
| 2003 | 10 |
| 2004 | 15 |
| 2005 | 24 |
| 2006 | 60 |
| 2007 | 49 |
| 2008 | 98 |
| 2009 | 84 |
| 2010 | 76 |
| 2011 | 62 |
| 2012 | 92 |
| 2013 | 89 |
| 2014 | 90 |
| 2015 | 81 |
| 2016 | 83 |
| 2017 | 56 |
| 2018 | 25 |
| 2019 | 33 |
| 2020 | 28 |
| 2021 | 23 |
| 2022 | 15 |
| 2023 | 14 |
| 2024 | 23 |
| 2025 | 15 |
| 2026 | 15 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 36
Who runs them
Industry 514 · Other 668
AstraZeneca (120) · Novo Nordisk A/S (108) · Merck Sharp & Dohme LLC (79) · Boehringer Ingelheim (77) · Takeda (38) · University at Buffalo (12) · University Hospital, Gentofte, Copenhagen (11) · Emory University (10)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,182
- Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With ObesityNot yet recruitingPhase 2Indiana UniversityNCT07823452Written as gut-brain axis (GLP-1)-activating food carbohydrate
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesRecruitingPhase 2Mayo ClinicNCT06976619Written as Liraglutide Pen Injector
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DICRecruitingPhase 4Tanta UniversityNCT07436663Written as Sitagliptin (DPP4 inhibitor)
- Combination Therapy for Alcohol Use DisorderNot yet recruitingPhase 2Johns Hopkins UniversityNCT07249554Written as Glucagon-Like Peptide-1 Agonist (GLP-1)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNot applicableThe University of Texas Health Science Center at San AntonioNCT02969798Written as Saxagliptin
- Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's DiseaseNot yet recruitingPhase 2Yonsei UniversityNCT07804381Written as Sitagliptin
- Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)RecruitingPhase 4University of VirginiaNCT03883412Written as Liraglutide
- A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 GliomasRecruitingPhase 2Case Comprehensive Cancer CenterNCT07003542Written as Sitagliptin
- Sitagliptin With Pembro in RCC and MelanomaRecruitingPhase 1Fernando Maciel BarbosaNCT07634380Written as Sitagliptin
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Sitagliptin
- Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)RecruitingPhase 1Novo Nordisk A/SNCT07225816Written as Liraglutide
- Sitagliptin in Recurrent/Progressive Grade 4 GliomaRecruitingPhase 1Kailin Yang, MD, PhDNCT07541781Written as Sitagliptin
- The Effects of LEUVATE on Glycemia, Insulinemia, Aminoacidemia, and Protein Synthesis in GLP-1 RA-treated AdultsNot yet recruitingNot applicableNutraceutical Innovations LLCNCT07595575Written as GLP-1
- Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRCRecruitingPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07365592Written as Sitagliptin (DPP4 inhibitor)
- Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeRecruitingPhase 4University of VirginiaNCT04575844Written as Liraglutide
- Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesRecruitingPhase 4Maisa N. Feghali, MDNCT05482789Written as Exenatide
- Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationRecruitingPhase 4Nabiqasim Industries (Pvt) LtdNCT06862739Written as Empagliflozin+Linagliptin+Metformin
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseRecruitingPhase 1Novo Nordisk A/SNCT07411560Written as Glucose-dependent Insulinotropic Polypeptide (GIP)
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesEnrolling by invitationPhase 4Bahria UniversityNCT07452913Written as Metformin+ Empagliflozin + Sitagliptin
- Effects of GH and Lirglutide on AgRPRecruitingPhase 4Columbia UniversityNCT05681299Written as liraglutide
Codes
What other systems call Incretins · ClinicalTrials.gg INT008908
- MeSH (NLM) D054795IncretinsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D054795 | Incretins | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.